Current Headlines

  1. Roche, Pharmacyclics Enter Cancer Combo Therapy Deal
    10/24/2014

    Pharmacyclics announced that it has signed into a master clinical drug supply agreement with Roche for an initial Phase 3 study of Pharmacyclics’ Imbruvica and Roche/Genentech’s Gazyva as a combination cancer therapy.

  2. Roche Invests $3B In Basel R&D Site
    10/24/2014

    Roche announced its commitment to invest 3 billion Swiss francs ($3.2 billion) over the next 10 years for its development plans that will include the construction of a new R&D site in Basel, Switzerland.

  3. Halozyme Gets FDA OK For 2 New Production Sites For Hylenex
    10/23/2014

    Biopharmaceutical company Halozyme Therapeutics announced that it has received the approval of the U.S. Food and Drug Administration (FDA) for its new contract manufacturing facilities that will be used to produce Hylenex recombinant (hyaluronidase human injection).

  4. Immunomedics Gets EU Orphan Status For Pancreatic Cancer ADC
    10/23/2014

    Clinical stage biopharmaceutical company Immunomedics announced that it has received Orphan Drug status for isactuzumab govitecan (IMMU-132) for the treatment of pancreatic cancer.

  5. FDA Accepts Merck’s, Sanofi’s BLA For Pediatric Hexavalent Vaccine
    10/23/2014

    Merck and Sanofi are a step closer to approval of their pediatric hexavalent vaccine, (DTaP5-IPV-Hib-HepB1), as the Food and Drug Administration (FDA) has accepted their Biologics License Application (BLA). The two companies announced the application acceptance in a press release, stating that the pediatric combination vaccine helps protect against six diseases.

  6. UCSF, CDRD Partner To Address ‘Valley of Death’ In Drug Development
    10/23/2014

    The University of California San Francisco (UCSF) and The Center for Drug Research and Development (CDRD) have partnered to address the ‘Valley of Death’, the phase between therapy discovery and commercialization. UCSF announced the partnership in a press release, stating that the collaboration seeks to take the University’s laboratory inventions into the marketing stage.

  7. Leading Researchers Join Biogen Idec To Advance Drug Discovery For Neurodegenerative Diseases
    10/23/2014

    Biogen Idec recently announced that two leading neuroscientists have joined the company to advance its research in neurodegenerative diseases. Christopher Henderson, Ph.D., joins as vice president, Neurology. Richard Ransohoff, M.D., joins as senior research fellow, Neuroimmunology.

  8. Karolinska Institutet Links With Moderna In mRNA Therapeutics
    10/22/2014

    Moderna Therapeutics, Karolinska Institutet (KI), and Karolinska University Hospital (KUH) have joined forces to discover and develop drugs using messenger RNA (mRNA) Therapeutics technology.

  9. AstraZeneca Bolsters Partnership With U Of Cambridge
    10/22/2014

    AstraZeneca and its global biologics R&D arm MedImmune announced four new collaborations with the University of Cambridge, all launched in an attempt to strengthen AZ’s existing partnership with the University as the company sets out to expand its research infrastructure in Cambridge.

  10. New Initiative Launched To Promote Biotech Education
    10/22/2014

    The Biogen Idec Foundation is offering up a $1.5 million grant in an effort to boost the biotechnology industry’s visibility.

Newsletter Signup
Newsletter Signup
By clicking Sign Me Up, you agree to our Terms and that you have read our Privacy Policy.